RMC No. 122-2020 clarifies VAT-exempt drug treatment using FDA-listed generic names or INNs, including salt forms, for medicine sellers and buyers.

Businesses selling, importing, purchasing, or accounting for medicines covered by the VAT-exempt drug rules must review whether their products fall within the clarified FDA list, because the exemption is determined by the International Non-Proprietary Name or generic name of the drug product, including salt forms. RMC No. 122-2020 matters now for pharmacies, hospitals, drug distributors, importers, wholesalers, and corporate accounting teams because VAT treatment should not be based only on brand names, product labels, or commercial descriptions; the controlling reference is the clarified FDA classification for VAT-exempt drugs under Joint AO No. 2-2018.

What RMC No. 122-2020 Changed

RMC No. 122-2020 published the clarification from the Food and Drug Administration concerning the list of VAT-exempt drugs under Joint Administrative Order No. 2-2018. The clarification relates to certain drug products previously included in the lists initially provided by the FDA and circulated through RMC No. 62-2020 and RMC No. 101-2020.

The key point is that the VAT exemption must be understood by reference to the International Non-Proprietary Name, also called the INN, or the generic name of the drug products. The clarification expressly includes salt forms. This is important because drug products in the market may appear under different brands, labels, or formulations, but the VAT analysis under the clarified list requires attention to the generic name and applicable salt form.

For business owners and accountants searching for VAT-exempt medicines Philippines, FDA VAT-exempt drugs list, RMC 122-2020 VAT exemption, RMC 62-2020 drugs, and RMC 101-2020 medicines, the practical takeaway is direct: confirm the generic name and salt form of the drug product before applying VAT-exempt treatment in sales invoices, purchases, inventory systems, and tax returns.

Who Is Most Affected

The businesses most affected are those directly involved in the sale, distribution, importation, procurement, and accounting of medicine products covered by the VAT-exempt drug rules. This includes pharmacies, hospital pharmacies, drugstores, pharmaceutical distributors, wholesalers, importers, healthcare institutions, and companies with substantial medicine procurement.

Corporate accountants, CFOs, tax managers, and in-house counsel should also pay attention because the VAT treatment of medicines affects invoicing, pricing, input tax accounting, tax mapping, BIR audit exposure, and documentation. If a company treats a product as VAT-exempt without verifying the applicable generic name and salt form, it may be exposed to later disputes during a BIR examination. Conversely, if a product is treated as VATable despite falling within the clarified list, the business may be overcharging VAT or misclassifying its transactions.

Internal Revenue Officers and other concerned persons were directed to be guided by the circular. This means that the clarification is not merely informational for private businesses; it is also a reference point for tax administration, review, and implementation by BIR personnel.

Key Compliance Requirement: Check the INN or Generic Name, Including Salt Forms

The most important compliance action under RMC No. 122-2020 is to verify whether the relevant drug product is covered by the clarified FDA list using the International Non-Proprietary Name or generic name, including salt forms. Businesses should not rely solely on brand names, marketing names, internal stock descriptions, supplier shorthand, or abbreviated product labels.

For example, the commercial identity of a medicine may differ from the scientific or generic identity relevant to the VAT exemption. The clarification confirms that the list should be read by reference to the INN or generic name, and that salt forms are included. Accounting and tax teams should therefore coordinate with pharmacists, regulatory officers, procurement teams, and suppliers to verify the exact generic name and salt form of each product being treated as VAT-exempt.

The circular also connects the clarification to earlier BIR issuances, specifically RMC No. 62-2020 and RMC No. 101-2020. Businesses that updated their VAT treatment based on those prior circulars should revisit their medicine master lists and product tax codes to confirm whether the FDA clarification affects existing classifications.

Effective Date and Deadlines

RMC No. 122-2020 is dated November 3, 2020. The circular does not state a separate future effectivity date, a transition period, or a special filing deadline. It also does not create a new VAT rate, new threshold, or new registration requirement. Instead, it publishes and implements the FDA clarification for guidance of internal revenue officers, employees, and others concerned.

Because no separate deadline is provided, affected businesses should treat the clarification as a current compliance reference for VAT classification of covered drug products. The practical deadline is operational: review the affected medicines before the next sales, purchase recording, tax return preparation, pricing update, or BIR audit response where the VAT status of those products may matter.

Penalties and Audit Risks for Non-Compliance

RMC No. 122-2020 does not state a specific penalty for failure to follow the clarification. However, VAT misclassification can still create ordinary tax compliance risks under the Tax Code and BIR audit practice. A seller that incorrectly treats a VATable product as VAT-exempt may face assessment exposure. A business that incorrectly treats an exempt product as VATable may create pricing, invoicing, customer, and accounting issues.

The higher practical risk is inconsistency. If the product master file, sales invoice settings, supplier documents, and tax return treatment do not align, the taxpayer may have difficulty defending its VAT position. During a BIR examination, the taxpayer should be ready to show why a medicine was classified as VAT-exempt, including documentation of the generic name or INN and any relevant salt form.

Practical Steps for Businesses

First, identify all medicine products currently treated as VAT-exempt under Joint AO No. 2-2018, RMC No. 62-2020, RMC No. 101-2020, and RMC No. 122-2020. The review should include active inventory, recently purchased products, imported products, and medicines sold through branches or hospital pharmacy systems.

Second, match each product against its International Non-Proprietary Name or generic name. Where applicable, verify the salt form. This should be done using regulatory, supplier, product registration, or pharmacy records rather than only commercial names.

Third, update accounting systems, point-of-sale systems, enterprise resource planning tax codes, and invoice templates so that VAT-exempt treatment is consistently applied only where supported. Businesses with multiple branches should ensure that all branches use the same VAT classification rules.

Fourth, retain supporting documents. These may include FDA-related references, supplier certifications, product registration details, internal tax memos, and screenshots or extracts from the product master file showing how the VAT classification was determined.

Finally, assign responsibility. The VAT-exempt drug classification issue should not be left solely to sales personnel or system encoders. It requires coordination among tax, accounting, procurement, regulatory affairs, and pharmacy personnel.

How Ablola, Saribong & Gueco Can Help

RMC No. 122-2020 is short, but its compliance impact can be significant for businesses that sell, distribute, import, or procure medicines. The important question is not only whether a medicine appears on a list, but whether the business can prove that its VAT treatment is correct based on the generic name or INN, including salt forms.

Ablola, Saribong & Gueco assists businesses with BIR compliance, VAT classification reviews, tax audit defense, invoicing issues, pharmaceutical and healthcare compliance, and documentation of tax positions. For companies that need to review VAT-exempt drug classifications, update accounting procedures, or prepare for a BIR audit, consult Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *